Home
Vimpat (VIM-pat) is the brand name used in the United States and some other countries for the seizure medicine lacosamide (la-COS-a-mide). In the United States, the Food and Drug Administration (FDA) approved lacosamide in 2008 to be used as an add-on (adjunctive) seizure medicine in adults with partial-onset epilepsy.
VIMPAT (lacosamide) tablets are indicated as adjunctive (add-on) therapy in the treatment of partial-onset (focal) seizures in patients with epilepsy aged 17 years and older. Usually, Vimpat is added when another seizure medicine is not controlling all seizures, rather than being used by itself; however, an experienced physician may choose to try Vimpat as a single agent in some circumstances.
Use can be in partial-onset seizures with or without secondary generalization to tonic-clonic (previously called grand mal) seizures.
VIMPAT (lacosamide) injection for intravenous use is indicated as add-on therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible, for example, due to illness or a surgical procedure.
Vimpat in Pregnancy Category C, indicating that increased mortality could be seen in pregnant rats given Vimpat. Whether or to what extent Vimpat causes birth defects in humans is not presently known. This indicates that caution is advised, but the benefits of the medication may outweigh the potential risks.
Talk to your doctor or another health professional if you are pregnant or plan to become pregnant. We don't yet have enough information to be able to estimate the risk of various types of birth defects that might occur if Vimpat is taken during pregnancy. We also don't know enough to compare the risk with Vimpat to the risk with other seizure medicines.
The risk of birth defects is generally higher for women who take more than one AED and for women with a family history of birth defects.
VIMPAT (lacosamide) tablets are indicated as adjunctive (add-on) therapy in the treatment of partial-onset (focal) seizures in patients with epilepsy aged 17 years and older. Usually, Vimpat is added when another seizure medicine is not controlling all seizures, rather than being used by itself; however, an experienced physician may choose to try Vimpat as a single agent in some circumstances.
Use can be in partial-onset seizures with or without secondary generalization to tonic-clonic (previously called grand mal) seizures.
VIMPAT (lacosamide) injection for intravenous use is indicated as add-on therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible, for example, due to illness or a surgical procedure.
Vimpat in Pregnancy Category C, indicating that increased mortality could be seen in pregnant rats given Vimpat. Whether or to what extent Vimpat causes birth defects in humans is not presently known. This indicates that caution is advised, but the benefits of the medication may outweigh the potential risks.
Talk to your doctor or another health professional if you are pregnant or plan to become pregnant. We don't yet have enough information to be able to estimate the risk of various types of birth defects that might occur if Vimpat is taken during pregnancy. We also don't know enough to compare the risk with Vimpat to the risk with other seizure medicines.
The risk of birth defects is generally higher for women who take more than one AED and for women with a family history of birth defects.
